Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Carlsmed (CARL) EBITDA Margin (2024 - 2026)

Carlsmed filings provide 2 years of EBITDA Margin readings, the most recent being 56.8% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 663.0% to 56.8% in Q4 2025 year-over-year; TTM through Dec 2025 was 57.56%, a N/A change, with the full-year FY2025 number at 58.67%, up 3063.0% from a year prior.
  • EBITDA Margin hit 56.8% in Q4 2025 for Carlsmed, up from 65.21% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 50.17% in Q4 2024 to a low of 118.56% in Q3 2024.